Moreover, tumor-infiltrating CD8+ T cells and PD-1 positive CD8+ T cells proportions were higher in the ACAA2-Overexpression group (Fig. 11E, F), implying that ACAA2 might serve as a promising immunotherapeutic target in RCC. This evidence concerns the gene CD8A and renal cell carcinoma.